Critical Role of a Novel Biological Marker GALNT14 Expression in Different Cancer Types

Turğut, Mehmet

doi:10.4172/2475-3203.1000e106

Cited by 1 publication

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The overexpression of GALNT14 is a strong biomarker correlated to the sensitivity of Apo2L/TRAIL-based anticancer therapy. GALNT14 alters cell migration and cellular morphology, and its overexpression causes malignancies, such as those of the breast, ovarium, lungs, and skin ( Erdal et al, 2017 ), so it is a good predictor of therapeutic outcomes, particularly of chemotherapy, in multiple cancers ( Lin and Yeh, 2020 ).…”

Section: Discussionmentioning

confidence: 99%

Identification of Candidate Therapeutic Genes for More Precise Treatment of Esophageal Squamous Cell Carcinoma and Adenocarcinoma

Polewko-Klim

Zhu

et al. 2022

Front. Genet.

View full text Add to dashboard Cite

The standard therapy administered to patients with advanced esophageal cancer remains uniform, despite its two main histological subtypes, namely esophageal squamous cell carcinoma (SCC) and esophageal adenocarcinoma (AC), are being increasingly considered to be different. The identification of potential drug target genes between SCC and AC is crucial for more effective treatment of these diseases, given the high toxicity of chemotherapy and resistance to administered medications. Herein we attempted to identify and rank differentially expressed genes (DEGs) in SCC vs. AC using ensemble feature selection methods. RNA-seq data from The Cancer Genome Atlas and the Fudan-Taizhou Institute of Health Sciences (China). Six feature filters algorithms were used to identify DEGs. We built robust predictive models for histological subtypes with the random forest (RF) classification algorithm. Pathway analysis also be performed to investigate the functional role of genes. 294 informative DEGs (87 of them are newly discovered) have been identified. The areas under receiver operator curve (AUC) were higher than 99.5% for all feature selection (FS) methods. Nine genes (i.e., ERBB3, ATP7B, ABCC3, GALNT14, CLDN18, GUCY2C, FGFR4, KCNQ5, and CACNA1B) may play a key role in the development of more directed anticancer therapy for SCC and AC patients. The first four of them are drug targets for chemotherapy and immunotherapy of esophageal cancer and involved in pharmacokinetics and pharmacodynamics pathways. Research identified novel DEGs in SCC and AC, and detected four potential drug targeted genes (ERBB3, ATP7B, ABCC3, and GALNT14) and five drug-related genes.

show abstract

Section: Discussionmentioning

confidence: 99%